SCNX (Scienture Holdings) Momentum Rank: 5 (As of Sep. 09, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCNX Scienture Holdings Inc SCNX
43 GF Score
Price $0.37
GF Value $0.51
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Scienture Holdings Momentum Rank?

Scienture Holdings SCNX +1.30% 43 Momentum Rank is 5 as of Sep. 09, 2026, which is at its 10-year median of 5.00. GuruFocus rates SCNX with a GF Score™ of 43/100 and a GF Value™ of $0.51 (Modestly Undervalued). The stock has 9 warning signs investors should review.

Scienture Holdings has the Momentum Rank of 5.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Scienture Holdings Momentum Rank Related Terms

SCNX vs PMHS, HEWA, BLMH: Momentum Rank Comparison

For the Pharmaceutical Retailers subindustry, Scienture Holdings's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scienture Holdings Momentum Rank vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Scienture Holdings's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Scienture Holdings's Momentum Rank falls into.


SCNX
43GF Score
Scienture Holdings Inc SCNX
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 5 mean?
Scienture Holdings (SCNX) has a Momentum Rank of 5 as of Sep. 09, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Scienture Holdings and its competitors. This is near median its historical median of 5.00. Over the past decade, Scienture Holdings' Momentum Rank has ranged from 1.00 to 10.00.
Is Scienture Holdings' Momentum Rank too high?
Scienture Holdings' current Momentum Rank of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Scienture Holdings has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scienture Holdings' Momentum Rank compare to PMHS and HEWA?
Scienture Holdings' Momentum Rank of 5 can be compared against companies in the Healthcare Providers & Services industry. Historically, Scienture Holdings' own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Healthcare Providers & Services company?
A good Momentum Rank depends on the Healthcare Providers & Services industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Scienture Holdings and its competitors. Scienture Holdings's current Momentum Rank is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scienture Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scienture Holdings (SCNX) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.51, compared to a current price of $0.37 — trading 28% below its estimated fair value. The current Momentum Rank is 5, which is near median its 10-year median of 5.00. Scienture Holdings' overall GF Score™ is 43/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Scienture Holdings (SCNX), the current Momentum Rank is 5 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scienture Holdings (SCNX) Overvalued in 2026?

Based on GuruFocus' analysis, Scienture Holdings stock appears to be undervalued. The current stock price of $0.37 is trading 28% below its estimated GF Value™ of $0.51. GuruFocus considers Scienture Holdings to be Modestly Undervalued.

Key valuation signals for SCNX:

  • Momentum Rank: 5 (near median its 10-year median of 5.00)
  • GF Value™: $0.51 vs. price of $0.37 (28% below fair value)
  • GF Score™: 43/100 with 9 warning signs

No single metric tells the full story. See the SCNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scienture Holdings Business Description

Other Exchanges 4E4:Germany
Address 20 Austin Boulevard, Commack, NY, USA, 11725
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
43GF Score

Get the complete analysis for SCNX

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.37
Price
$0.51
GF Value